Evidence map›Paper›PMID 35244716›Full record

ArticleInternational journal of epidemiology2022

Opium use and risk of bladder cancer: a multi-centre case-referent study in Iran.

Maryam Hadji, Hamideh Rashidian, Maryam Marzban, Ahmad Naghibzadeh-Tahami, Mahin Gholipour, Elham Mohebbi, Roya Safari-Faramani, Monireh Sadat Seyyedsalehi, Bayan Hosseini, Mahdieh Bakhshi and 25 more

Abstract readMulticenter Study
In one paragraph

Article in International journal of epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Evaluation of the Effects of Opium on the Expression ofBladder cancer (Amsterdam, Netherlands) · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Maryam HadjiHealth Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland.ORCID 0000-0001-5486-7513
Hamideh RashidianCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Maryam MarzbanDepartment of Public Health, School of Public Health, Bushehr University of Medical Science, Bushehr, Iran.
Ahmad Naghibzadeh-TahamiSocial Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Mahin GholipourMetabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Elham MohebbiCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Roya Safari-FaramaniResearch Center for Environmental Determinants of Health, School of Public Health, Kermanshah Medical Sciences University, Kermanshah, Iran.
Monireh Sadat SeyyedsalehiCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Bayan HosseiniCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Mahdieh BakhshiHealth Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Reza Alizadeh-NavaeiGastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Lida AhmadiColorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abbas RezaianzadehColorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abdolvahab MoradiGolestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.
Alireza Ansari-MoghaddamHealth Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Azim NejatizadehTobacco and Health Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.ORCID 0000-0001-6347-0163
Soodabeh ShahidSalesCancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Farshad ZohrabiDepartment of Urology, School of Medicine, Busher University of Medical Science, Bushehr, Iran.
Reza MohammadiNeuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Mohammad Reza NowrooziUro-Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Hossein PoustchiLiver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Dariush NasrollahzadehInternational Agency for Research on Cancer, Lyon, France.
Farid NajafiResearch Center for Environmental Determinants of Health, School of Public Health, Kermanshah Medical Sciences University, Kermanshah, Iran.
Ali Akbar HaghdoostDepartment of Biostatistics and Epidemiology, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0003-4628-4849
Afarin Rahimi-MovagharIranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
Arash EtemadiDigestive Oncology Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Ali MohagheghiCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Reza MalekzadehLiver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Paul BrennanInternational Agency for Research on Cancer, Lyon, France.
Joachim SchüzInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-9687-2134
Paolo BoffettaStony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA.
Elisabete WeiderpassInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-2237-0128
Farin KamangarDepartment of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, USA.
Kazem ZendehdelCancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Eero PukkalaHealth Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland.

Funding

Upper Gastrointestinal Cancer StudiesZIACP000185 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ABNET, CHRISTIAN · 2009 to 2025
$25.6M
World Health Organization 001
6 · The paper itself

Abstract

backgroundBladder cancer (BC) is the 10th most common type of cancer worldwide and the fourth most common type of cancer in Iran. Opium use is considered as one of the risk factors for BC. We aim to assess the association between various parameters of opium use, which in Iran is mainly ingested or smoked in various forms, and the risk of BC.

methodIn this multi-centre case-referent study in Iran, 717 BC cases and 3477 referents were recruited to the study from May 2017 until July 2020. Detailed histories of opium use (duration, amount, frequency) and potential confounders were collected by trained interviewers. Multivariable unconditional logistic regression models were used to measure adjusted odds ratio (OR) and 95% confidence intervals (CI). The ORs were adjusted for age, gender, place of residence and pack-years of cigarette smoking.

resultsRegular opium consumption was associated with an increased risk of BC (OR 3.5, 95% CI: 2.8, 4.3) compared with subjects who never used opium. Compared with continuous users, the risk decreased to one-third for those who stopped opium more than 10 years ago. The adjusted OR for those who used both crude opium (teriak) and opium juice was 7.4 (95% CI: 4.1, 13.3). There was a joint effect of opium and tobacco (OR for users of both opium and tobacco 7.7, 95% CI: 6.0, 9.7).

conclusionsRegular opium use is associated with an approximately 4-fold risk for BC. The OR decreases along with the increasing time since stopping opium use.

Indexed as

Opium DependenceUrinary Bladder NeoplasmsCase-Control StudiesHumansIranOpiumRisk FactorsOpiumbladder cancerIROPICANopium

Identifiers

PMID35244716
PMCPMC9189939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.